ReviewCurrent HIV/AIDS reports2009
Accessories to the crime: recent advances in HIV accessory protein biology.
Review in Current HIV/AIDS reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Article
- Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy.PLoS computational biology · 2012Article
- Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase.The Journal of biological chemistry · 2011Article
- Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection.Journal of virology · 2011Article
- Nuclear RNA export and packaging functions of HIV-1 Rev revisited.Journal of virology · 2010Article
- Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain.Cell host & microbe · 2010Article
- Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?Retrovirology · 2010Review
- Antisense transcription in gammaretroviruses as a mechanism of insertional activation of host genes.Journal of virology · 2010Article
- Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.Expert reviews in molecular medicine · 2010Review
- Clinical implications of new findings in HIV basic research.HIV therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent advances in understanding the roles of the lentiviral accessory proteins have provided fascinating insight into the molecular biology of the virus and uncovered previously unappreciated innate immune mechanisms by which the host defends itself. HIV-1 and other lentiviruses have developed accessory proteins that counterattack the antiviral defenses in a sort of evolutionary battle. The virus is remarkably adept at co-opting cellular degradative pathways to destroy the protective proteins. This review focuses on recent advances in understanding three of the accessory proteins-virion infectivity factor (Vif), viral protein R (Vpr), and viral protein U (Vpu)-that target different restriction factors to ensure virus replication. These proteins may provide promising targets for the development of novel classes of antiretroviral drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.